"Gout Suppressants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.
| Descriptor ID |
D006074
|
| MeSH Number(s) |
D27.505.954.329.337
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gout Suppressants".
Below are MeSH descriptors whose meaning is more specific than "Gout Suppressants".
This graph shows the total number of publications written about "Gout Suppressants" by people in this website by year, and whether "Gout Suppressants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gout Suppressants" by people in Profiles.
-
Abhishek A, Cipolletta E, Nakafero G, Avery AJ, Mamas M, Tata LJ. Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink. Ann Rheum Dis. 2022 Dec; 81(12):1768-1769.
-
Kaul S, Gupta M, Bandyopadhyay D, Hajra A, Deedwania P, Roddy E, Mamas M, Klein A, Lavie CJ, Fonarow GC, Ghosh RK. Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. Am J Cardiovasc Drugs. 2021 Sep; 21(5):499-512.
-
Juraschek SP, Appel LJ, Miller ER. Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. Am J Hypertens. 2017 Sep 01; 30(9):871-875.
-
Qaseem A, Harris RP, Forciea MA. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 03; 166(1):58-68.
-
Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017 04; 46(5):594-600.
-
Soloway S, Tucker BS. Calcium Pyrophosphate Dihydrate Deposition Disease in a Knee With Total Joint Replacement. J Clin Rheumatol. 2016 Aug; 22(5):277.
-
Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
-
Juraschek SP, Kovell LC, Miller ER, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015 Apr; 67(4):588-92.
-
Knorr JP, Chewaproug D, Neeli S, Torres E, Zaki R. Severe Interferon/Ribavirin-Induced Hyperuricemia and Urate Nephropathy Requiring Rasburicase and Hemodialysis in a Liver Transplant Recipient. Exp Clin Transplant. 2015 Dec; 13(6):596-9.
-
Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014 Nov 04; 161(9):659-67.